Pfizer quarterly profits beat market estimates
31 October, 2017
Pfizer’s quarterly profit beat market estimates, in part helped by higher-than-expected sales of its blockbuster pneumonia vaccine Prevnar.
Pfizer sold $1.52 billion worth of Prevnar in the third quarter, down nearly 1 per cent from a year earlier, but ahead of analysts’ estimate of $1.46 billion.
For more on this story: